GE could inhibit the abnormal proliferation of peripheral blood lymphocytes (PBL) and FLS, repair the lower proliferation activity of mesenteric lymph node lymphocytes (MLNL), reduce the level of pro-inflammatory cytokines and increase anti-inflammatory cytokine production, and down-regulate the expression of p-JNK in PBL and MLNL, p-ERK1/2 in MLNL, and p-p38MAPK in PBL and FLS, thereby effectively relieving RA [14,15,16,17,18]. The gene discussed is MAPK3; the disease is rheumatoid arthritis.